24-h Energy Expenditure and Anti-obesity Medication

Launched by UNIVERSITY OF PISA · Jun 18, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how two medications, Semaglutide and Tirzepatide, affect the body’s energy use over 24 hours and changes in body fat and muscle. These medicines are designed to help with weight loss, and the study will look at how they impact metabolism (how your body burns energy) and body composition using a special scan called DXA, which measures fat and muscle.

People who might join this study are adults with a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher if they also have other health issues related to weight. Participants need to have had a fairly stable weight recently and be generally healthy without serious heart problems or diabetes. Women who could become pregnant will need to take a pregnancy test and use birth control. If accepted, participants will follow the study plan over time, which includes taking the medication and having their energy use and body composition measured. This study has not started recruiting yet, but it aims to better understand how these medications work to support long-term weight management.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Body mass index (BMI) \>= 30 kg/m² or \>= 27 kg/m² with at least one weight-related comorbidity and stable body weight (±2 kg in prior 3 months)
• • informed consent, adherence to study protocol, negative pregnancy test and contraception use (if applicable), and absence of cardiovascular events or end-organ damage.
• Exclusion Criteria:
• • psychiatric conditions impairing adherence, history of medullary thyroid cancer, pregnancy/lactation
• • diabetes